Patient characteristics
| Patient no. . | Age, y . | FVIII:C (IU/dL) . | Inhibitor (BU/mL) . | Clinical BPA response before TG testing . |
|---|---|---|---|---|
| 1 | 42 | < 1 | 21 | Bad responder to APCC; weak efficacy of rFVIIa |
| 2 | 50 | < 1 | 18 | Good responder to APCC |
| 3 | 36 | < 1 | 9 | Good responder to APCC |
| 4 | 40 | < 1 | 78 | Bad responder to both APCC and rFVIIa |
| 5 | 71 | < 1 | 10.5 | Bad responder to APCC; weak efficacy of rFVIIa |
| 6 | 33 | < 1 | 24 | Good responder to rFVIIa; weak efficacy of APCC |
| Patient no. . | Age, y . | FVIII:C (IU/dL) . | Inhibitor (BU/mL) . | Clinical BPA response before TG testing . |
|---|---|---|---|---|
| 1 | 42 | < 1 | 21 | Bad responder to APCC; weak efficacy of rFVIIa |
| 2 | 50 | < 1 | 18 | Good responder to APCC |
| 3 | 36 | < 1 | 9 | Good responder to APCC |
| 4 | 40 | < 1 | 78 | Bad responder to both APCC and rFVIIa |
| 5 | 71 | < 1 | 10.5 | Bad responder to APCC; weak efficacy of rFVIIa |
| 6 | 33 | < 1 | 24 | Good responder to rFVIIa; weak efficacy of APCC |